DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent

Journal Article · · Journal of the American Chemical Society

Human parainfluenza virus 3 (HPIV3) and respiratory syncytial virus (RSV) cause lower respiratory infection in infants and young children. There are no vaccines for these pathogens, and existing treatments have limited or questionable efficacy. Infection by HPIV3 or RSV requires fusion of the viral and cell membranes, a process mediated by a trimeric fusion glycoprotein (F) displayed on the viral envelope. Once triggered, the pre-fusion form of F undergoes a series of conformational changes that first extend the molecule to allow for insertion of the hydrophobic fusion peptide into the target cell membrane and then refold the trimeric assembly into an energetically stable post-fusion state, a process that drives the merger of the viral and host cell membranes. Peptides derived from defined regions of HPIV3 F inhibit infection by HPIV3 by interfering with the structural transitions of the trimeric F assembly. Here we describe lipopeptides derived from the C-terminal heptad repeat (HRC) domain of HPIV3 F that potently inhibit infection by both HPIV3 and RSV. The lead peptide inhibits RSV infection as effectively as does a peptide corresponding to the RSV HRC domain itself. We show that the inhibitors bind to the N-terminal heptad repeat (HRN) domains of both HPIV3 and RSV F with high affinity. Finally, co-crystal structures of inhibitors bound to the HRN domains of HPIV3 or RSV F reveal remarkably different modes of binding in the N-terminal segment of the inhibitor.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
USDOE; National Institutes of Health (NIH)
Grant/Contract Number:
R01AI114736; R01AI121349; AC02-06CH11357; 085P1000817; 1S10OD012289
OSTI ID:
1562709
Journal Information:
Journal of the American Chemical Society, Vol. 141, Issue 32; ISSN 0002-7863
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (33)

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis journal May 2010
The Cell Biology of Acute Childhood Respiratory Disease: Therapeutic Implications journal October 2006
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study journal September 2017
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection journal August 2014
Viral membrane fusion journal July 2008
Paramyxovirus Fusion and Entry: Multiple Paths to a Common End journal April 2012
Mechanisms of Virus Membrane Fusion Proteins journal November 2014
Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. journal March 1996
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. journal December 1994
Peptides Corresponding to the Heptad Repeat Sequence of Human Parainfluenza Virus Fusion Protein Are Potent Inhibitors of Virus Infection journal September 1996
A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. journal November 1995
Sulfono-γ-AA modified peptides that inhibit HIV-1 fusion journal January 2018
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes journal March 2004
Molecular Determinants of Antiviral Potency of Paramyxovirus Entry Inhibitors journal October 2007
Prevention of Measles Virus Infection by Intranasal Delivery of Fusion Inhibitor Peptides journal January 2015
In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence journal January 2017
Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides journal March 2017
Inhibition of Nipah Virus Infection In Vivo: Targeting an Early Stage of Paramyxovirus Fusion Activation during Viral Entry journal October 2010
Viral Entry Inhibitors Targeted to the Membrane Site of Action journal July 2010
A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity journal May 2012
Lipophilicity is a key factor to increase the antiviral activity of HIV neutralizing antibodies journal April 2017
Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway Epithelium journal December 2004
The Effect of Respiratory Synctial Virus on Chemokine Release by Differentiated Airway Epithelium journal January 2004
Human Parainfluenza Virus Infection of the Airway Epithelium: Viral Hemagglutinin-Neuraminidase Regulates Fusion Protein Activation and Modulates Infectivity journal July 2009
Features of Circulating Parainfluenza Virus Required for Growth in Human Airway journal May 2016
Adaptation of Human Parainfluenza Virus to Airway Epithelium Reveals Fusion Properties Required for Growth in Host Tissue journal July 2012
Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein journal June 2005
Structural characterization of the human respiratory syncytial virus fusion protein core journal December 2000
Capping and α-helix stability journal November 1989
The entry of entry inhibitors: A fusion of science and medicine journal September 2003
Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates journal March 2018
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections journal March 2005
A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol journal August 2017

Cited By (2)

Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition journal March 2020
Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy journal February 2020